Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
11.61
+0.52 (4.69%)
At close: Jun 15, 2026, 4:00 PM EDT
11.35
-0.26 (-2.24%)
After-hours: Jun 15, 2026, 7:39 PM EDT
Oculis Holding AG Employees
Oculis Holding AG had 60 employees as of December 31, 2025. The number of employees increased by 11 or 22.45% compared to the previous year.
Employees
60
Change (1Y)
11
Growth (1Y)
22.45%
Revenue / Employee
$23,334
Profits / Employee
-$1,965,541
Market Cap
701.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 60 | 11 | 22.45% |
| Dec 31, 2024 | 49 | 13 | 36.11% |
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
| Sep 30, 2022 | 32 | - | - |
| Jun 30, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CorMedix | 191 |
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Solid Biosciences | 121 |
| Aura Biosciences | 113 |
| CytomX Therapeutics | 69 |
| Candel Therapeutics | 55 |
| Design Therapeutics | 54 |
OCS News
- 4 days ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire
- 5 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 6 days ago - Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - GlobeNewsWire
- 7 days ago - Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 12 days ago - Oculis price target lowered to $23 from $42 at JPMorgan - TheFly
- 13 days ago - Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - GlobeNewsWire
- 13 days ago - Oculis price target lowered to $38 from $49 at Baird - TheFly